These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28144893)

  • 1. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
    Green DJ; Bensinger WI
    Curr Hematol Malig Rep; 2017 Feb; 12(1):61-67. PubMed ID: 28144893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.
    Bashir Q; Qazilbash MH
    Curr Hematol Malig Rep; 2017 Apr; 12(2):126-135. PubMed ID: 28285435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
    Koehne G; Giralt S
    Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.
    Rosiñol L; Jiménez R; Rovira M; Martínez C; Fernández-Avilés F; Marín P; Suárez-Lledó M; Gutiérrez-García G; Fernández de Larrea C; Carreras E; Urbano-Ispizua A; Bladé J
    Bone Marrow Transplant; 2015 May; 50(5):658-62. PubMed ID: 25621810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
    Festuccia M; Martino M; Ferrando F; Messina G; Moscato T; Fedele R; Boccadoro M; Giaccone L; Bruno B
    Expert Opin Biol Ther; 2015 Jun; 15(6):857-72. PubMed ID: 25865214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
    Kawamura K
    Int J Hematol; 2023 Aug; 118(2):193-200. PubMed ID: 37060508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
    Karp Leaf R; Cho HJ; Avigan D
    Curr Hematol Malig Rep; 2015 Dec; 10(4):395-404. PubMed ID: 26338470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.
    Ramasamy K; Mahmood S; Lim Z; Corderoy S; Devereux S; Mufti GJ; Pagliuca A; Schey S
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):242-5. PubMed ID: 21575930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
    Nishihori T; Alsina M
    Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
    Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW
    Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic.
    Mir MA; Kapoor P; Kumar S; Pandey S; Dispenzieri A; Lacy MQ; Dingli D; Hogan W; Buadi F; Hayman S; Gandhi M; Gertz MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):349-357.e2. PubMed ID: 25958193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
    Castagna L; Mussetti A; Devillier R; Dominietto A; Marcatti M; Milone G; Maura F; de Philippis C; Bruno B; Furst S; Blaise D; Corradini P; Montefusco V
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1549-1554. PubMed ID: 28499937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in allogeneic transplantation for multiple myeloma.
    Gahrton G
    Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
    Zeiser R; Finke J
    Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for multiple myeloma: is there a future?
    Dhakal B; Vesole DH; Hari PN
    Bone Marrow Transplant; 2016 Apr; 51(4):492-500. PubMed ID: 26726943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.